{
    "1": {
        "question": "What percentage of latent HSV DNA was eliminated in mouse models of genital infection using AAV-delivered meganucleases?",
        "options": {
            "A": "50%",
            "B": "70%",
            "C": "80%",
            "D": "90%",
            "E": "97%",
            "F": "I don't know"
        }
    },
    "2": {
        "question": "Which AAV serotype combination led to improvements in tolerability by simplifying the regimen?",
        "options": {
            "A": "AAV9 only",
            "B": "AAV9 and AAV-Dj/8",
            "C": "AAV9, AAV-Dj/8, and AAV-Rh10",
            "D": "AAV-Dj/8 and AAV-Rh10",
            "E": "AAV-Rh10 only",
            "F": "I don't know"
        }
    },
    "3": {
        "question": "In the article, what was used to pharmacologically reactivate latent HSV-1?",
        "options": {
            "A": "Heat stress",
            "B": "UV light exposure",
            "C": "JQ1 bromodomain inhibitor",
            "D": "Depo Provera",
            "E": "Electroconvulsive shock",
            "F": "I don't know"
        }
    },
    "4": {
        "question": "What part of the HSV genome do the meganucleases m5 target?",
        "options": {
            "A": "ICP0 gene",
            "B": "UL19 gene",
            "C": "UL30 gene",
            "D": "LAT region",
            "E": "gB gene",
            "F": "I don't know"
        }
    },
    "5": {
        "question": "How did the combination therapy impact hepatotoxicity in treated mice?",
        "options": {
            "A": "Increased hepatotoxicity significantly",
            "B": "Decreased hepatotoxicity",
            "C": "No impact on hepatotoxicity",
            "D": "Eliminated hepatotoxicity completely",
            "E": "Caused severe liver failure",
            "F": "I don't know"
        }
    },
    "6": {
        "question": "Which promoter type showed improved tolerability by reducing neurotoxicity in the study?",
        "options": {
            "A": "Beta-actin promoter",
            "B": "Ubiquitous CBh promoter",
            "C": "Neuronal-specific promoter (e.g., E/CamKII)",
            "D": "CMV promoter",
            "E": "SV40 promoter",
            "F": "I don't know"
        }
    },
    "7": {
        "question": "What is the primary concern for infected persons that this study addresses?",
        "options": {
            "A": "Reduction in ganglionic viral loads",
            "B": "Symptomatic relief",
            "C": "Higher virulence of HSV-1",
            "D": "Viral shedding and risk of transmission",
            "E": "Resistance to existing antivirals",
            "F": "I don't know"
        }
    },
    "8": {
        "question": "What percentage of viral shedding was reduced in treated mice after gene editing?",
        "options": {
            "A": "30%",
            "B": "50%",
            "C": "70%",
            "D": "95%",
            "E": "100%",
            "F": "I don't know"
        }
    },
    "9": {
        "question": "What animal model was prominently used for testing HSV-1 infection and treatment in the study?",
        "options": {
            "A": "Rats",
            "B": "Guinea pigs",
            "C": "Non-human primates",
            "D": "Swiss Webster mice",
            "E": "C57BL/6 mice",
            "F": "I don't know"
        }
    },
    "10": {
        "question": "What is the significance of using the JQ1 reactivation model in this study?",
        "options": {
            "A": "It mirrors human HSV reactivation patterns exactly.",
            "B": "It allows studying spontaneous reactivation without external triggers.",
            "C": "It induces a quantifiable and reproducible form of HSV reactivation.",
            "D": "It results in permanent elimination of HSV from ganglia.",
            "E": "It is the most effective antiviral treatment known.",
            "F": "I don't know"
        }
    },
    "11": {
        "question": "Which cell-type specific promoter was associated with decreased liver toxicity?",
        "options": {
            "A": "Neuronal CamKII promoter",
            "B": "Ubiquitous SV40 promoter",
            "C": "Viral CMV promoter",
            "D": "Ubiquitous CBh promoter",
            "E": "Neuronal Synapsin promoter",
            "F": "I don't know"
        }
    },
    "12": {
        "question": "How were HSV-1-specific meganucleases delivered to mice in this study?",
        "options": {
            "A": "Electroporation",
            "B": "Intravenous injection",
            "C": "Adenovirus vectors",
            "D": "AAV vectors",
            "E": "Liposomal delivery",
            "F": "I don't know"
        }
    },
    "13": {
        "question": "Which animal strain showed similar results for viral load reduction to Swiss Webster mice?",
        "options": {
            "A": "BALB/c mice",
            "B": "Wistar rats",
            "C": "C57BL/6 mice",
            "D": "Golden Syrian hamsters",
            "E": "F344 rats",
            "F": "I don't know"
        }
    },
    "14": {
        "question": "What was the observed effect of lower doses of AAV on hepatotoxicity?",
        "options": {
            "A": "Increased hepatotoxicity",
            "B": "No change in hepatotoxicity",
            "C": "Decreased hepatotoxicity",
            "D": "Total elimination of hepatotoxicity",
            "E": "Induced kidney toxicity instead",
            "F": "I don't know"
        }
    },
    "15": {
        "question": "What additional method besides gene editing was used to test HSV reactivation in this study?",
        "options": {
            "A": "Ultraviolet radiation",
            "B": "Hyperthermic stress",
            "C": "Electric shocks",
            "D": "Chemical stressors",
            "E": "Hormonal stimulation",
            "F": "I don't know"
        }
    },
    "16": {
        "question": "What percentage of animals exhibited clinical signs of hepatotoxicity at a high AAV dose?",
        "options": {
            "A": "1%",
            "B": "5%",
            "C": "10%",
            "D": "20%",
            "E": "50%",
            "F": "I don't know"
        }
    },
    "17": {
        "question": "In which type of ganglia was the HSV viral load largely reduced after meganuclease therapy?",
        "options": {
            "A": "Dorsal root ganglia (DRG)",
            "B": "Trigeminal ganglia (TG)",
            "C": "Superior cervical ganglia (SCG)",
            "D": "Cervical lymph nodes",
            "E": "Spleen tissue",
            "F": "I don't know"
        }
    },
    "18": {
        "question": "What was the impact of the alternative AAV9-m4 therapy on liver inflammation?",
        "options": {
            "A": "It increased liver inflammation.",
            "B": "It decreased liver inflammation.",
            "C": "It did not change liver inflammation.",
            "D": "It eliminated liver inflammation.",
            "E": "It caused inflammatory foci to appear in the spleen.",
            "F": "I don't know"
        }
    },
    "19": {
        "question": "The use of which therapy component aimed to avoid high complexity in clinical settings?",
        "options": {
            "A": "Use of a broad-spectrum antiviral",
            "B": "Combination of multiple serotypes of AAV",
            "C": "Use of a single meganuclease",
            "D": "Use of combination vaccines",
            "E": "Small molecular inhibitors",
            "F": "I don't know"
        }
    },
    "20": {
        "question": "Which factor was associated with more efficient reduction of ganglionic viral loads over time?",
        "options": {
            "A": "Increased animal age",
            "B": "Use of immunosuppressive drugs",
            "C": "Higher doses of antiviral drugs",
            "D": "Duration of meganuclease therapy",
            "E": "Use of broader-spectrum meganucleases",
            "F": "I don't know"
        }
    },
    "21": {
        "question": "What was a key outcome of employing AAV9-m4 AAV vectors in the study?",
        "options": {
            "A": "Increased neurotoxicity",
            "B": "Reduced ganglionic viral loads",
            "C": "Minimal effects on viral loads",
            "D": "Increased liver toxicity",
            "E": "Enhanced HSV reinfection rates",
            "F": "I don't know"
        }
    },
    "22": {
        "question": "How effective was the AAV9 serotype on its own compared to the combination serotypes for viral load decrease?",
        "options": {
            "A": "Less effective",
            "B": "Equally effective",
            "C": "More effective",
            "D": "Not effective at all",
            "E": "It had no impact",
            "F": "I don't know"
        }
    },
    "23": {
        "question": "What was the main goal achieved by using neuron-specific promoters?",
        "options": {
            "A": "Enhancing the reach of the therapy",
            "B": "Reducing the cost of therapy",
            "C": "Decreasing off-target gene editing",
            "D": "Minimizing hepatotoxicity and neurotoxicity",
            "E": "Increasing the duration of therapy",
            "F": "I don't know"
        }
    },
    "24": {
        "question": "Which meganuclease was tested for its potential to reduce peripheral virus shedding?",
        "options": {
            "A": "m3",
            "B": "m5",
            "C": "m7",
            "D": "m10",
            "E": "m4",
            "F": "I don't know"
        }
    },
    "25": {
        "question": "In which type of model was the efficacy of JQ1 in inducing HSV shedding confirmed?",
        "options": {
            "A": "In vitro cell models",
            "B": "Ocular infection mouse model",
            "C": "Guinea pig infection model",
            "D": "Cell-free DNA models",
            "E": "Viral culture assays",
            "F": "I don't know"
        }
    },
    "26": {
        "question": "What was used as a measure to analyze virus shedding frequency and quantity post-therapy?",
        "options": {
            "A": "Antiviral resistance profiling",
            "B": "Swab-based real-time PCR",
            "C": "ELISA for viral antigens",
            "D": "Western blot for viral proteins",
            "E": "Sequencing-based viral detection",
            "F": "I don't know"
        }
    },
    "27": {
        "question": "During the study, how were clinical signs of hepatoxicity monitored in mice?",
        "options": {
            "A": "Ultrasound scanning",
            "B": "Weight and health observations",
            "C": "CT imaging",
            "D": "ECG monitoring",
            "E": "Liver enzyme blood tests",
            "F": "I don't know"
        }
    },
    "28": {
        "question": "What approach was used to gauge meganuclease expression levels in the study?",
        "options": {
            "A": "Microarray analysis",
            "B": "Flow cytometry",
            "C": "Western blot and immunostaining",
            "D": "qPCR for transgene markers",
            "E": "Mass spectrometry",
            "F": "I don't know"
        }
    },
    "29": {
        "question": "What did the meta-analysis of several experiments primarily focus on?",
        "options": {
            "A": "Quantification of AAV vector stability",
            "B": "Comparison of different meganuclease targets",
            "C": "Efficacy and safety of gene editing over time",
            "D": "Analysis of HSV-2 vs. HSV-1 infection models",
            "E": "Effectiveness of immunosuppressive co-treatments",
            "F": "I don't know"
        }
    },
    "30": {
        "question": "What did the meta-analysis find about the relationship between AAV/meganuclease treatment and viral shedding?",
        "options": {
            "A": "No relationship was found",
            "B": "Viral shedding increased with treatment",
            "C": "Viral shedding was significantly reduced with treatment",
            "D": "Viral shedding was unchanged",
            "E": "Indeterminate results",
            "F": "I don't know"
        }
    },
    "31": {
        "question": "In terms of genome editing efficiency, which ganglia showed the largest reduction in latent HSV?",
        "options": {
            "A": "Superior cervical ganglia",
            "B": "Dorsal root ganglia",
            "C": "Trigeminal ganglia",
            "D": "Ciliary ganglia",
            "E": "Sphenopalatine ganglia",
            "F": "I don't know"
        }
    },
    "32": {
        "question": "Which factor primarily drove the selective effectiveness of AAV transduction in various ganglia?",
        "options": {
            "A": "Blood/ganglionic barrier permeability",
            "B": "Previous infection rates",
            "C": "Ganglia size",
            "D": "Surface receptor expression",
            "E": "Density of neuronal cells",
            "F": "I don't know"
        }
    },
    "33": {
        "question": "The stochastic nature of JQ1-induced HSV shedding is similar to which human condition?",
        "options": {
            "A": "Continuous virus replication",
            "B": "Long-term virus dormancy",
            "C": "Episodic virus shedding and transmission",
            "D": "Chronic fatigue syndrome",
            "E": "Acute HSV symptoms",
            "F": "I don't know"
        }
    },
    "34": {
        "question": "What did the use of neuron-specific promoters in the study demonstrate?",
        "options": {
            "A": "Increased gene editing precision",
            "B": "Increased hepatotoxicity",
            "C": "Improved safety with better neuron targeting",
            "D": "Reduced need for AAV vectors",
            "E": "Enhanced immune response avoidance",
            "F": "I don't know"
        }
    },
    "35": {
        "question": "For what other virus is JQ1 proposed as a latency-reversing agent, besides HSV?",
        "options": {
            "A": "HPV",
            "B": "EBV",
            "C": "HIV",
            "D": "CMV",
            "E": "VZV",
            "F": "I don't know"
        }
    },
    "36": {
        "question": "Has any form of clinical testing of gene editing for HSV been reported outside of animal models?",
        "options": {
            "A": "Yes, in a randomized controlled trial",
            "B": "Yes, in an open-label single-arm trial",
            "C": "No, not to date",
            "D": "Yes, but results were inconclusive",
            "E": "No, pending regulatory approval",
            "F": "I don't know"
        }
    },
    "37": {
        "question": "What is the main target of gene therapies discussed in this article for curing HSV?",
        "options": {
            "A": "Reducing surface antigen expression",
            "B": "Blocking HSV entry receptors",
            "C": "Editing latent viral DNA within ganglia",
            "D": "Inhibiting viral assembly proteins",
            "E": "Modulating host immune response",
            "F": "I don't know"
        }
    },
    "38": {
        "question": "In animal studies, very high doses of AAV could potentially result in what outcome?",
        "options": {
            "A": "Bone marrow suppression",
            "B": "Increased viability of HSV",
            "C": "Severe liver toxicity",
            "D": "Improved therapeutic efficiency",
            "E": "Irreversible muscle atrophy",
            "F": "I don't know"
        }
    },
    "39": {
        "question": "What was the potential benefit highlighted for achieving HSV shedding levels below 104 copies?",
        "options": {
            "A": "Increased antiviral resistance",
            "B": "Total elimination of HSV infection",
            "C": "Greatly reduced or eliminated transmission risks",
            "D": "Longer durations between reactivations",
            "E": "Improved immune response",
            "F": "I don't know"
        }
    },
    "40": {
        "question": "Which statistical approach was used to evaluate overall findings of the study on viral shedding?",
        "options": {
            "A": "Bayesian inference",
            "B": "Linear regression analysis",
            "C": "Meta-analysis using mixed models",
            "D": "Survival analysis",
            "E": "Single-blind randomized trials",
            "F": "I don't know"
        }
    },
    "41": {
        "question": "What is the primary advantage of using JQ1 in HSV studies?",
        "options": {
            "A": "It completely prevents shedding.",
            "B": "It enhances immune memory against HSV.",
            "C": "It allows consistent reactivation and shedding measurement.",
            "D": "It reduces the need for animal models.",
            "E": "It protects against liver toxicity.",
            "F": "I don't know"
        }
    },
    "42": {
        "question": "What was the role of HEK293 and Vero cell lines in this study?",
        "options": {
            "A": "Stem cell generation",
            "B": "AAV vector production",
            "C": "Culture for HSV replication",
            "D": "Murine fibroblast experimentation",
            "E": "Genome sequencing",
            "F": "I don't know"
        }
    },
    "43": {
        "question": "Which ganglia type exhibited higher HSV load reductions in the study?",
        "options": {
            "A": "Trigeminal ganglia",
            "B": "Superior cervical ganglia",
            "C": "Dorsal root ganglia",
            "D": "Sphenopalatine ganglia",
            "E": "Olfactory bulb",
            "F": "I don't know"
        }
    },
    "44": {
        "question": "Which mouse strain was primarily used in the study for infection models?",
        "options": {
            "A": "BALB/c",
            "B": "Swiss Webster",
            "C": "C57BL/6",
            "D": "FVB/N",
            "E": "DBA/2",
            "F": "I don't know"
        }
    },
    "45": {
        "question": "Which experimental measure was used to demonstrate the stochasticity of HSV shedding?",
        "options": {
            "A": "Observation of molecular weight changes",
            "B": "Analysis of cell replication rates",
            "C": "Tracking of ocular swab viral loads",
            "D": "Measure of blood pressure fluctuations",
            "E": "Recording of neural electric impulses",
            "F": "I don't know"
        }
    },
    "46": {
        "question": "Which expression method was used to test the ICF in liver sections?",
        "options": {
            "A": "PCR analysis",
            "B": "ELISA",
            "C": "Mass spectrometry",
            "D": "Histological H&E staining",
            "E": "In situ hybridization",
            "F": "I don't know"
        }
    },
    "47": {
        "question": "Which HSV-1 protein-coded regions were targeted by the dual meganuclease therapy?",
        "options": {
            "A": "Major capsid protein VP5 and surface glycoproteins",
            "B": "ICP0 and UL19 genes",
            "C": "UL19 and UL30 genes",
            "D": "VP5 and LAT regions",
            "E": "Immediate early genes only",
            "F": "I don't know"
        }
    },
    "48": {
        "question": "What percentage reduction was found in the dual meganuclease therapy meta-analysis?",
        "options": {
            "A": "48%",
            "B": "60%",
            "C": "70%",
            "D": "75%",
            "E": "80%",
            "F": "I don't know"
        }
    },
    "49": {
        "question": "Which delivery method showed the smallest levels of liver inflammation in liver experiments?",
        "options": {
            "A": "Retro-orbital injections",
            "B": "Single serotype AAV9 delivery",
            "C": "Triple AAV serotype delivery",
            "D": "Liposomal vector delivery",
            "E": "Dorsal root ganglia injections",
            "F": "I don't know"
        }
    },
    "50": {
        "question": "Which statistical model confirmed the reduction of HSV shedding after therapy?",
        "options": {
            "A": "Single sample t-test",
            "B": "Kaplan-Meier curve",
            "C": "Generalized linear mixed models",
            "D": "ANOVA",
            "E": "Chi-square test",
            "F": "I don't know"
        }
    }
}